Cancer Risks and Survival Outcomes in Lynch Syndrome in South Africa
Author Information
Author(s): Ndou Lutricia, Chambuso Ramadhani, Algar Ursula, Boutall Adam, Goldberg Paul, Ramesar Raj
Primary Institution: University of Cape Town
Hypothesis
What are the cancer spectrum, cumulative risk, and survival outcomes for Lynch syndrome variant heterozygotes with pathogenic variants in the MLH1 and MSH2 genes in South Africa?
Conclusion
Lynch syndrome variant heterozygotes with pathogenic variants in the MLH1 and MSH2 genes show significant differences in cancer risk and survival outcomes based on gene and sex.
Supporting Evidence
- LSVH with MLH1 variants had a younger age at cancer diagnosis compared to those with MSH2 variants.
- CRC was the most common cancer diagnosed in both MLH1 and MSH2 LSVH.
- Female LSVH had a higher incidence of extracolonic cancers compared to male LSVH.
Takeaway
This study looked at people in South Africa with a specific genetic condition that makes them more likely to get certain cancers. It found that the type of cancer and how well people do can depend on their genes and whether they are male or female.
Methodology
A retrospective study analyzed demographic, clinical, and genetic data from a Lynch syndrome registry in South Africa over 30 years, using statistical tests to assess differences and survival outcomes.
Potential Biases
Potential biases may arise from the limited geographic and ethnic diversity of the sample.
Limitations
The study had a relatively small sample size for some genes and lacked detailed surveillance and treatment data.
Participant Demographics
The majority of participants were of mixed ancestry, with a higher proportion of females in the MSH2 group.
Statistical Information
P-Value
p = 0.015 for age at cancer diagnosis difference between MLH1 and MSH2 groups.
Confidence Interval
95% CI for survival rates reported.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website